99 related articles for article (PubMed ID: 6211234)
1. Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
Van Amburg AL; Presant CA; Burns D
Cancer Treat Rep; 1982 Jun; 66(6):1431-3. PubMed ID: 6211234
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of piperazinedione in malignant melanoma: a report by the Southeastern Cancer Study Group.
Presant CA; Bartolucci AA; Ungaro P; Oldham R
Cancer Treat Rep; 1979 Aug; 63(8):1367-9. PubMed ID: 476710
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors.
Silver BA; Barlock AL; Lippman ME; Anderson T; Fisher RI
Cancer Treat Rep; 1982 May; 66(5):1229-30. PubMed ID: 6211231
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma.
Ahmann DL; Frytak S; Kvols LK; Hahn RG; Edmonson JH; Bisel HF; Creagan ET
Cancer Treat Rep; 1980; 64(4-5):721-3. PubMed ID: 6448689
[No Abstract] [Full Text] [Related]
5. Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.
Mouridsen HT; Bramwell VH; Lacave J; Metz R; Vendrik C; Hild J; McCreanney J; Sylvester R
Cancer Treat Rep; 1981; 65(5-6):509-11. PubMed ID: 6453646
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of chlorozotocin in patients with malignant melanoma.
Houghton AN; Camacho FJ; Gralla RJ; Wittes R
Cancer Treat Rep; 1981; 65(7-8):705-6. PubMed ID: 6454487
[No Abstract] [Full Text] [Related]
7. Vindesine for metastatic malignant melanoma. A phase II trial.
Nelimark RA; Peterson BA; Vosika GJ; Conroy JA
Am J Clin Oncol; 1983 Oct; 6(5):561-4. PubMed ID: 6613921
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
Creagan ET; Ahmann DL; Schutt AJ; Green SJ
Cancer Treat Rep; 1982 Jun; 66(6):1425-6. PubMed ID: 7083244
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of carboplatin in advanced malignant melanoma.
Evans LM; Casper ES; Rosenbluth R
Cancer Treat Rep; 1987 Feb; 71(2):171-2. PubMed ID: 3542209
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of chlorozotocin.
Gralla RJ; Tan CT; Young CW
Cancer Treat Rep; 1979 Jan; 63(1):17-20. PubMed ID: 154363
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of diglycoaldehyde in malignant melanomas and soft tissue sarcomas.
Vosika GJ; Briscoe K; Carey RW; O'Donnell JF; Perry MC; Budman D; Richards F; Coleman M
Cancer Treat Rep; 1981; 65(9-10):823-5. PubMed ID: 7273013
[TBL] [Abstract][Full Text] [Related]
13. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma.
Berman E; Casper ES; Howard J; Wittes RE
Cancer Treat Rep; 1984 Apr; 68(4):679-80. PubMed ID: 6585272
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma.
Samson MK; Baker LH; Cummings G; Talley RW; McDonald B; Bhathena DB
Cancer Treat Rep; 1982 Feb; 66(2):371-3. PubMed ID: 6459845
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).
Creech RH; Stanley K; Vogl SE; Ettinger DS; Bonomi PD; Salazar O
Cancer Treat Rep; 1982 Jun; 66(6):1417-9. PubMed ID: 6282460
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
Creagan ET; Schutt AJ; Ahmann DL; Green SJ
Cancer Treat Rep; 1982 Dec; 66(12):2089-90. PubMed ID: 7139650
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients.
Neifeld JP; Tormey DC; Baker MA; Meyskens FL; Taub RN
Cancer Treat Rep; 1983 Feb; 67(2):155-7. PubMed ID: 6825122
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of chlorozotocin in metastatic sarcomas.
Presant CA; Bartolucci AA
Med Pediatr Oncol; 1984; 12(1):25-7. PubMed ID: 6230516
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of chlorozotocin in metastatic malignant melanoma.
Hoth DF; Schein PS; Winokur S; Woolley PV; Robichaud K; Binder RB; Smith FP
Cancer; 1980 Oct; 46(7):1544-7. PubMed ID: 6448088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
